Catalio Capital Management

Catalio Capital Management is a multi-strategy investment firm focused on breakthrough biomedical technology and innovative healthcare companies. Founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein, Catalio specializes in private equity, private credit, and public equities strategies, supporting companies from inception through to IPO or acquisition. The firm’s portfolio includes notable companies such as Affini-T, which is developing precision T-cell therapeutics for solid tumors, and Boost Neuroscience, focusing on therapies to combat cognitive aging and neurodegeneration. Catalio has also invested in companies like Octant, Inc., and Pheast Therapeutics, demonstrating a strong commitment to advancing precision medicines and novel cancer therapies. Catalio's strategy involves close collaboration with their portfolio companies, leveraging a network of over 36 world-renowned scientists to identify and invest in cutting-edge biomedical technologies. This approach has led to successful investments in companies like Thrive Earlier Detection, which was acquired by EXACT Sciences for $2.15 billion, and Personal Genome Diagnostics, acquired by LabCorp for $500 million.